Sun Sep 15 16:08:54 UTC 2024: ## Becton, Dickinson and Company (BDX) Sees Institutional Investor Activity

**New York, NY – September 15, 2024** – HBK Sorce Advisory LLC reduced its stake in medical instruments supplier Becton, Dickinson and Company (BDX) by 3.6% during the second quarter, according to a recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor now holds 3,052 shares, worth $713,000.

Other institutional investors and hedge funds also made changes to their positions in BDX during the quarter. Livelsberger Financial Advisory, OLD Point Trust & Financial Services N A, Scarborough Advisors LLC, Rise Advisors LLC, and ICA Group Wealth Management LLC all acquired new stakes in the company. Overall, institutional investors and hedge funds own 86.97% of BDX’s stock.

BDX shares opened at $234.18 on Friday, with a market capitalization of $67.69 billion. The company has a price-to-earnings ratio of 51.58, a PEG ratio of 1.91, and a beta of 0.42. The company recently announced a quarterly dividend of $0.95, payable on September 30th to shareholders of record on September 9th.

BDX has been the subject of several recent analyst reports. Evercore ISI, Citigroup, StockNews.com, Raymond James, and Stifel Nicolaus have all adjusted their price targets and ratings for the company. Currently, one investment analyst has rated BDX as a “Hold,” while eight have assigned a “Buy” rating, resulting in a consensus rating of “Moderate Buy” with an average price target of $279.50.

Becton, Dickinson and Company specializes in the development, manufacturing, and distribution of medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More